Agios Pharmaceuticals (AGIO) Assets Average (2013 - 2026)

Agios Pharmaceuticals (AGIO) has 14 years of Assets Average data on file, last reported at $1.1 billion in Q2 2026.

• Quarterly Assets Average fell 24.23% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (down 24.23% YoY) and the FY2025 annual result came in at $1.5 billion, up 13.85% from the prior year.
• Assets Average declined to $1.1 billion in Q2 2026, from $1.2 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.7 billion in Q4 2024 to a low of $811.4 million in Q2 2024.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average slumped 40.68% — and 2025, when it jumped 86.52%.
• Tracing AGIO's Assets Average over 5 years: stood at $1.2 billion in 2022, then retreated by 19.62% to $972.2 million in 2023, then soared by 77.69% to $1.7 billion in 2024, then decreased by 22.35% to $1.3 billion in 2025, then decreased by 14.52% to $1.1 billion in 2026.
• The last three Assets Average figures came in at $1.1 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.